BioLineRx Company Insiders

BioLineRx Management Team Effectiveness

The company has return on total asset (ROA) of (0.1536) % which means that it has lost $0.1536 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4594) %, meaning that it created substantial loss on money invested by shareholders. BioLineRx's management efficiency ratios could be used to measure how well BioLineRx manages its routine affairs as well as how well it operates its assets and liabilities. The market capitalization of BioLineRx is $15.18 Million. BioLineRx shows 3.99 percent of its outstanding shares held by insiders and 1.07 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company. Some institutional investors establish a significant position in stocks such as BioLineRx in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of BioLineRx, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

BioLineRx Workforce Comparison

The company has Profit Margin (PM) of (0.45) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (7.58) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $7.58.

BioLineRx Benchmark Summation

BioLineRx Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as BioLineRx often depends on how effective the management is. BioLineRx management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioLineRx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioLineRx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in BioLineRx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioLineRx. Check BioLineRx's Beneish M Score to see the likelihood of BioLineRx's management manipulating its earnings.

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.